If You Invested in Xcelerate Inc (XCRT)

XCELERATE INC (XCRT) is a medical, health and wellness company that trades on the OTCQB market. According to company disclosures, Xcelerate adopted a new business plan in May 2020 focused on integrating non-medical technologies into medical applications and building related healthcare businesses.

The company describes three separate but related business areas. First, Xcelerate is involved in the formulation, packaging and marketing of consumer health and beauty, clinically tested skin care products. This activity has included operations conducted through ESN Group, which marketed over-the-counter healthcare and personal care products under brands such as Ceramedx and Earth Science Naturals. In an October 2025 press release, Xcelerate announced the sale of its majority interest in the ESN Group of companies in an all-cash transaction to Noble Labs Holdings, LLC, stating that the divestiture was intended to allow the company to refocus on its original medical technology mission and remove merchant finance debt attributable to ESN from its balance sheet.

Second, Xcelerate is pursuing the development of AI and virtual health technology to assist patients in developing countries in obtaining medical care. Through its majority-owned subsidiary AfiyaSasa Africa, LLC, the company has articulated a goal of launching an AI-assisted patient portal in Tanzania. Xcelerate has described a modified business plan that includes acquiring a clinical care setting in which its virtual health technology can be trialed, tested and applied. Management has characterized AfiyaSasa as a platform designed to connect patients in remote areas to clinicians using AI-assisted diagnostics and virtual care, with the stated aim of expanding access to healthcare and creating opportunities for sustainable revenue.

Third, Xcelerate reports that it is engaged in owning and licensing the rights to various forms of medical equipment and a portfolio of patents, patents pending and technology licenses. The company has highlighted ongoing work on medical device intellectual property, including a Surgical Tool with Targeting Guidance. In an August 2024 announcement, Xcelerate stated that it had commenced the nationalization process for two PCT international patent applications corresponding to U.S. utility applications filed with the United States Patent and Trademark Office. The company describes the key innovation of these patents as introducing a "first-person view" to the surgical theatre by integrating cameras directly into surgical tools, with potential benefits that include improved precision and speed, reduced surgical site size, integrated illumination and the ability to project targeting markers.

Across these activities, Xcelerate emphasizes the use of AI-driven healthcare solutions and the application of non-medical engineering advances to clinical and medical care. The company has indicated that AI is central to its strategy, particularly in relation to the AfiyaSasa platform. It has also reported efforts to expand and protect its intellectual property through patent filings in multiple jurisdictions, including applications in the European Union and China, as part of the nationalization of its PCT filings.

Xcelerate has also communicated that it is a reporting company with the SEC pursuant to Regulation A and has discussed filing annual and semi-annual reports, as well as registration statements on Form S-1 and amendments to those filings. The company has described steps taken to change auditors, re-audit historical financial statements, and pursue an application to list its common stock on a national securities exchange, while also engaging an investment bank to provide investment banking and up-listing advisory services. These disclosures are presented by the company as part of its broader plan to support its business development in medical devices, virtual health technology and consumer health and beauty products.

In shareholder communications and press releases, Xcelerate has also referenced a digital strategy intended to enhance engagement with shareholders and stakeholders. This includes plans to update its corporate website to highlight AI initiatives, AfiyaSasa project milestones and patent developments, and to increase its presence on social media channels by sharing information and insights from its leadership team.

Business Focus and Segments

Based on the company’s own descriptions, Xcelerate’s activities can be grouped into the following core areas:

• Consumer health and beauty / clinically tested skin care products, historically including over-the-counter healthcare products and personal care brands operated through ESN Group, which the company later sold.
• AI and virtual health technology aimed at extending the reach of physicians and supporting patients in developing countries, initially focused on Africa through AfiyaSasa Africa, LLC.
• Medical equipment and intellectual property, including ownership and licensing of medical devices and related patents, patents pending and technology licenses, with specific reference to surgical tools incorporating targeting guidance and first-person view capabilities.

Geographic and Market Orientation

The company has highlighted developing countries, initially in Africa, as a focus for its virtual health technology, with particular reference to Tanzania through AfiyaSasa Africa, LLC. It has also referenced patent activities that involve multiple markets, including member states of the European Union and other countries such as China, Ireland, Japan and Mexico, in connection with the nationalization of its PCT patent applications.

Intellectual Property and Technology

Xcelerate’s disclosures place significant emphasis on patents and technology licenses. The company has described its mission as leveraging non-medical engineering advancements and intellectual property for clinical and medical care. Its PCT and U.S. patent filings relate to surgical tools that integrate imaging and targeting functions, and it has reported filing additional patent applications in the EU and China. These efforts are presented as part of a broader strategy to develop and protect medical device technologies that can be licensed or deployed in clinical settings.

Corporate Communications

In its press releases, Xcelerate has noted that it seeks to enhance transparency and communication with shareholders and stakeholders. The company has mentioned initiatives such as updating its corporate website to better present its AI initiatives, virtual health projects and patent portfolio, and increasing its social media activity to provide progress updates and commentary from its leadership.

FAQs about XCELERATE INC (XCRT)